Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in trials to assess its potential.
The authors' work 3, however, primarily highlights the role of memory B-cell IL-10 in downregulating the active inflammatory response in EAE (that is, disease remission), less so the role of B ...
The National Institute for Health and Care Excellence (NICE) has recommended Pharming’s Joenja (leniolisib) to treat patients with the ultra-rare immune disease, activated phosphoinositide 3-kinase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback